Categories: News

Albireo to Report Second Quarter 2021 Financial Results on August 5

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

— Conference call and webcast to be held at 10:00 a.m. ET —

BOSTON, July 29, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 5, 2021, to provide a business update and review the company’s financial results for the second quarter ended June 30, 2021.

To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13720893. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.

About Albireo

Albireo Pharma is a rare liver disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s product, Bylvay, was approved by the U.S. FDA as the first for the treatment of pruritus in patients with all sub-types of progressive familial intrahepatic cholestasis (PFIC), and is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media Contact: 
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com 

Investor Contact: 
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578  

Staff

Recent Posts

OrthoMinds, LLC Provides Notice of a Data Security Event

ALPHARETTA, Ga., March 20, 2025 /PRNewswire/ -- OrthoMinds, LLC ("OrthoMinds") is providing notice of a…

2 minutes ago

HealthMark Named a Top Workplace in 2025 by USA Today

HealthMark Group celebrates another year as a USA Today Top Workplace honoree, which recognizes companies…

2 minutes ago

Danaher Schedules First Quarter 2025 Earnings Conference Call

WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its…

6 hours ago

Angelalign Technology Achieves Steady Growth in 2024, Driven by Global Expansion and Digital Innovation

SAN CLEMENTE, Calif., March 20, 2025 /PRNewswire/ -- Angelalign Technology Inc. ("Angelalign Technology" or the "Company")…

6 hours ago

Steer Health Launches SteerConnect: The First AI-Powered Digital Gateway to Streamline Patient Care Access

Innovative platform eliminates endless scrolling and care dead-ends with smart triage, personalized care matching, and…

6 hours ago

Sciton Inc. Recognized as a 2025 Top Workplace USA for the Fourth Consecutive Year

PALO ALTO, Calif., March 20, 2025 /PRNewswire/ -- Sciton Inc., a global leader in laser…

6 hours ago